P0707Comparison of Effectiveness Between Vedolizumab and Ustekinumab in Ulcerative Colitis: A Real-World Multicenter Study from GunTURK IBD Group-Türkiye

Background Data comparing the efficacy and safety of vedolizumab and ustekinumab for ulcerative colitis remained limited. This multicenter real-world study was designed to compare the clinical efficacy and safety of vedolizumab and ustekinumab in biologic-experienced ulcerative colitis patients Methods Retrospective data of patients who were treated with vedolizumab or ustekinumab from 2020 to 2024 was collected from 14 centers. The outcomes included steroid-free clinical remission, clinical remission, treatment persistence and adverse events at week 14-16, 52 and 104. Propensity score adjustment with inverse probability treatment weighting was applied. Results A total of 420 patients were included (vedolizumab: 260, ustekinumab: 160). At week 14-16 and week 52, in the weighted cohort, two drugs were comparable for steroid-free clinical remission and clinical remission (p > 0.05). Although steroid-free clinical remission rates were similar, clinical remission rate was more favorable with vedolizumab, compared to ustekinumab at week 104 (aOR = 0.66; 95%CI 0.45-0.91) (Tabe 1). Among patients with one biologic history, clinical remission (aOR = 0.51; 95%CI 0.35-0.74) and steroid-free clinical remission (aOR = 0.57; 95%CI 0.38-0.85) rates for vedolizumab were better than ustekinumab at week 104. For patients with history of ≥ 2 biologic agent, ustekinumab performed better for clinical remission (aOR = 1.86; 95%CI 1.10-3.16) and steroid-free clinical remission (aOR = 1.79; 95%CI 1.05-3.09) at week 52 (Figure 1). Treatment persistence throughout the treatment was significantly better for ustekinumab (aOR = 1.82; 95%CI 1.36-2.44). Severe adverse event rate was similar for both groups. Conclusion Both drugs have acceptable and similar clinical response rates and safety profile with few exceptions. Conflict of interest: Dr. Araz, Filiz: No conflict of interest Sezgin, Orhan: No conflict of interest Barutcu, Sezgin: Unal, Nalan Gulsen: No conflict of interest Bengi, Goksel: no conflicts Ozseker, Burak: No conflict of interest Karaogullarindan, Umit: No conflict of interest Hakim, Gozde: No conflict of interest Özer, Birol: No conflict of interest Akpinar, Hale: No conflict of interest Oruç, Nevin: No conflict of interest Gişi, Kadir: No conflict of interest Atay, Kadri: No conflict of interest Kara, Banu: No conflict of interest Kasap, Elmas: No conflict of interest Cekin, Ayhan Hilmi: No conflict of interest Yilmaz, Nimet: No conflict of interest Altintas, Engin: No conflict of interest Ates, Fehmi: No conflict of interest Ucbilek, Enver: No conflict of interest Harput, Zekiye Nur: none Şahan, Mehmet Ali: No conflict of interest Dolu, Süleyman: No conflict of interest Mamadov, Etibar: No conflict of interest Odabaş, Emre: No conflict of interest Tuncel, Elif Tuğba: No conflict of interest Kuş, Mesut: No conflict of interest Tasdogan, Burcak Evren: No conflict of interest Akbay Harmandar, Ferda: No conflict of interest Seydaoğlu, Gülşah: No conflict of interest Aykut, Mert Burak: No conflict of interest Kara, Taner: No conflict of interest Çapar, Halil: No conflict of interest Çetin, Duran Deha: No conflict of interest Atar, Galip Egemen: No conflict of interest Yücel, Sevinç Püren: No conflict of interest